Apoptosis signal-regulating kinase 1 (ASK1) plays an essential role in stress and immune response and has been linked to the development of several diseases. Here, we present the structure of the human ASK1 catalytic domain in complex with staurosporine. Analytical ultracentrifugation (AUC) and crystallographic analysis showed that ASK1 forms a tight dimer (Kd ∼ 0.2 μM) interacting in a head-to-tail fashion. We found that the ASK1 phosphorylation motifs differ from known ASK1 phosphorylation sites but correspond well to autophosphorylation sites identified by mass spectrometry. Reporter gene assays showed that all three identified in vitro autophosphorylation sites (Thr813, Thr838, Thr842) regulate ASK1 signaling, but site-directed mutants showed catalytic activities similar to wild-type ASK1, suggesting a regulatory mechanism independent of ASK1 kinase activity. The determined high-resolution structure of ASK1 and identified ATP mimetic inhibitors will provide a first starting point for the further development of selective inhibitors.
Published: October 16, 2007
Apoptosis signal-regulating kinase 1 (ASK1, also called MAP3K5) is a mitogen-activated protein kinase kinase kinase (MAP3K) that plays an essential role in cellular stress and the immune response (
ASK1 has been linked to several diseases and has been discussed as a target for pharmaceutical intervention (
Human ASK1 is a polypeptide of 1,374 residues consisting of a central serine/threonine kinase domain and coiled-coil domains in both the N and C termini (
Activated ASK1 directly phosphorylates MKK3/MKK6 and MKK4/MKK7, resulting in activation of the p38 and JNK MAPKs, respectively. A consensus docking site of 24 amino acids, called the DVD domain, is located in the C terminus of MKKs and has been proposed to interact with the kinase domain of ASK1, thus promoting the specific targeting of these downstream kinases (
Here, we present the high-resolution structure of the kinase domain of ASK1 in complex with the generic protein kinase inhibitor staurosporine. We show that the ASK1 catalytic domain is dimeric in solution and that it is an active kinase in its unphosphorylated state. We identified a consensus recognition sequence for ASK1 by peptide library screening that is in agreement with in vitro autophosphorylation sites identified by mass spectrometry. The high-resolution crystal structure together with the in vitro characterization of this enzyme provide a basis for the further understanding of ASK1 regulation and for the development of specific inhibitors for this interesting target.
The ASK1 catalytic domain structure displays a typical protein kinase fold comprising the five β sheets and helix αC constituting the small lobe (residues 670–757) and a larger mainly alpha helical C-terminal lobe (residues 761–940) (
ASK1 is only distantly related in sequence to kinases of known structure. Superimposition with the catalytic domain of its next structural neighbor PAK1 (PDB code:
Staurosporine binds to the ATP binding site of ASK1 in a mode that has been described for a number of kinase-staurosporine complexes (
Although not phosphorylated, the activation segment was well defined by electron density except for the unstructured tip of the activation loop (residues 832–836). Interestingly, the conserved αC glutamate (Glu725) forms a hydrogen bond with the main-chain nitrogen of the DFG motif residue Phe823, whereas the conserved active site lysine (Lys709), which usually forms a salt bridge with the αC glutamate in active kinases, also hydrogen bonds to the main chain of Phe823 (
Full-length ASK1 has been described as a dimeric molecule stabilized in vivo by coiled-coil domain located C-terminal to the catalytic domain. Consequently, dimerization of the kinase domain was not an anticipated finding. Analysis of crystal packing revealed that the two ASK1 molecules in the asymmetric unit dimerize with their own symmetry equivalent. Both molecules bury a total surface area of about 1,997 Å2 consisting of 473 Å2 of hydrophobic and 1524 Å2 of hydrophilic surface. In order to verify the dimeric state of the ASK1 kinase domain in solution, we carried out analytical ultracentrifugation experiments (
The interaction between ASK1 monomers is based primarily on shape complementarity over a large surface area spanning almost the entire length of the protein. To achieve such a tight interaction, the molecules associate in a head-to-tail fashion with the N-terminal domain of one molecule interacting with the C-terminal domain of the other molecule and vice versa. The two catalytic sites are on the same side of the dimer near the equatorial plane and around 20 Å apart. Interaction between the molecules involves a number of direct hydrogen bonds (Leu700-Asn776', Asn702-Tyr783', Gln703-Thr779', and Arg705-Thr813' [and vice versa]), as well as water-mediated hydrogen bonds (Gln756-HOH-Tyr814') (the apostrophe denotes the symmetry equivalent molecule). In addition, multilayer π-stacking and hydrophobic interactions Arg705-Tyr814'-Pro758/Pro758'-Tyr814-Arg705' may also contribute to dimerization (
One of the identified phosphorylation sites (Thr813) is located in the dimer interface, and phosphorylation at this residue is likely to result in formation of hydrogen bonds to Arg705 located in the interacting protomer. We were therefore interested to explore if phosphorylation at Thr813 effects dimerization of ASK1. However, AUC data indicated that dephosphorylated ASK1 (mixture between de- and monophosphorylated ASK1) homogeneously triphosphorylated ASK1 as well as a T813A mutant formed all stable dimers in solution, and sedimentation equilibrium experiments revealed similar association behavior (
In order to determine the sequence specificity of active site-mediated phosphorylation, we screened a peptide library with recombinant ASK1 (
The mass spectrum of the intact recombinant protein treated with ATP/Mg2+ clearly indicated the presence of at least three phosphorylation sites (
A second site was identified at Thr838, which is located in the activation segment. In our structure, the side chain of Thr838 is oriented toward the solvent, and phosphorylation at this site is not expected to stabilize the activation segment in the absence of structural rearrangements. Furthermore, as described above, the neighboring residue Glu837 forms interactions typically formed by a phosphate moiety located at the corresponding position within the activation segment. However, Thr838 has been shown to play an essential role in activation of ASK1 by oxidative stress (
To study the role of each of the identified autophosphorylation sites, we cloned site-directed alanine mutants into an expression vector and studied the effects of the mutations in transient transfection assays, monitoring JNK/p38 reporter gene activity. As expected from earlier studies, mutation of Thr838 drastically reduced reporter gene activity when compared to unstimulated control levels. Interestingly, mutation of the other two sites also provided a significant reduction in ASK1 function (
Furthermore, we studied the effect of the site-directed alanine mutants on kinase catalytic activity in vitro. Recombinant ASK1 mutants autophosphorylated rapidly and had specific activities that were comparable to wild-type ASK1 (data not shown). To test if the generated ASK1 mutants are also active on specific ASK1 substrates, we reconstituted a minimal ASK1 signaling cascade (ASK1-MKK6-p38) in vitro with recombinant MKK6 and His6-p38α by detecting p38 phosphorylation with an antibody specific for phosphorylated p38. Surprisingly, all three mutants showed catalytic activity in this in vitro phosphorylation experiment comparable to wild-type ASK1, suggesting that phosphorylation at the three catalytic domain autophosphorylation sites may be required for the recruitment of signaling partners and ASK1 substrates to this large signalosome rather than for regulation of catalytic activity.
ASK1 shares only moderate sequence homology with the catalytic domains of other human protein kinases. Apart from its closely related isoform ASK2 (MAP3K6) the next phylogenetic neighbors share sequence identities of only about 50% with the ASK1 catalytic domain. As a consequence, the structure of ASK1 determined in this study represents a chemically diverse kinase catalytic domain.
Recombinant ASK1 was found to be catalytically active and rapidly autophosphorylated at Thr813, Thr838, and Thr842 in vitro. Even though recombinant ASK1 is catalytically active, the structure of ASK1 was found to assume a catalytically not competent conformation as indicated by the distal position of αC from the active site, the conformation of the DFG motif that would not allow binding of a metal ion and by the partial disorder of the activation loop tip. Inactive conformations are quite frequently observed in active kinases and reflect the dynamic nature of the kinase catalytic domain (
Thr842 forms a hydrogen bond with the catalytic aspartate residue, which is destroyed by mutating this residue to alanine. However, the recombinant protein is still active and phosphorylates specific substrates (e.g., MKK6) with similar activity than wild-type ASK1. Interestingly, the analogous position in the activation segment has also been described as a regulatory phosphorylation site for DAPK3 (Thr150) (
Surprisingly, the ASK1 activation loop conformation does not explain how phosphorylation on Thr838 influences ASK1 activity, and interestingly, the mutant Thr838Ala is catalytic active and recognizes both autophosphorylation sites as well as specific substrates with similar efficiency as wild-type ASK1 in vitro. Thus, it is likely that in the absence of Thr838 phosphorylation, the neighboring residue Glu837 mimics hydrogen bond patterns typically formed by an activating phosphate moiety (
Such a conformational change is likely to contribute to the peptide phosphorylation specificity that we observed for ASK1. The serine-threonine kinases PKA and PKB/Akt are phosphorylated at activation loop sites analogous to that of ASK1 Thr838 and like ASK1, have a preference for hydrophobic, particularly aromatic residues at the +1 position in their substrates. In these kinases, two residues form a hydrophobic pocket that accommodates residues found at the +1 position in substrates: the residue immediately upstream of the APE sequence that terminates the activation loop (analogous to Met846 of ASK1) and the residue immediately downstream of the phosphorylated Thr within the loop (analogous to Phe839 of ASK1) (
In contrast to the autophosphorylation sites, which closely match the determined consensus sequence, several of the ASK1 phosphorylation sites on downstream MKK substrates do not. Phosphorylation of these nonconsensus sites may be driven by complex formation between ASK1 and the MKKs, which could overcome a specific sequence requirement at the phosphorylation site. Alternatively, structural changes in the activation segment that may impact phosphorylation site selectivity could be induced by binding of an ASK1 substrate to the DVD docking site. Significant rearrangement of the activation segment has recently been reported for the MAPK ERK2 upon engagement of a docking site (
This study revealed that the catalytic domain of ASK1 also dimerizes independently of C-terminal coiled-coil domains. ASK1 has been reported to hetero-oligomerize with the closely related protein ASK2 (MAP3K6) (
ASK1 has been suggested to be a potential target for the treatment of polyglutamine (polyQ) diseases (
Human ASK1 (residues 659–951; gi|5174547) was subcloned into the T7 expression vector SGC-pLIC. The protein was expressed as an N-terminally His6-tagged fusion protein with a tobacco etch virus (TEV) protease cleavage site by using
A 10 ml overnight culture was used to inoculate 1 l of Terrific Broth media containing 100 μg/ml kanamycin. Cultures were grown at 37°C until the OD600 reached ∼2.0. After that, the temperature was adjusted to 25°C, and expression was induced for 18 hr with 1 mM IPTG. Cells were centrifuged and pellets were resuspended in binding buffer (50 mM HEPES [pH 7.5], 300 mM NaCl, 20 mM imidazole including a protease inhibitor cocktail [Complete, Roche]) and lysed with a high-pressure homogenizer. The lysate was cleared by centrifugation, and the protein was purified by Ni-affinity chromatography with a wash buffer (50 mM HEPES [pH 7.5], 1 M NaCl, 20 mM Imidazole) and an elution buffer of the same composition but containing 250 mM imidazole. The eluted protein was treated with lambda and alkaline phosphatase together with TEV protease for 12 hr at 4°C to remove phosphorylation and the His6-tag, respectively. The eluted fraction was further purified by gel filtration chromatography with Superdex S75 (60 × 1 cm) column equilibrated in 10 mM HEPES (pH 7.5), 500 mM NaCl, 5% (w/v) glycerol. DTT was added to the protein sample to a final concentration of 10 mM, and the protein was concentrated to 13 mg/ml. Purity and integrity of ASK1 were confirmed by SDS/PAGE and electrospray ionization time-of-flight mass spectrometry (Aglient LC-ESI TOF).
Sedimentation velocity experiments were carried out on a Beckman XL-I Analytical Ultracentrifuge equipped with a Ti-50 rotor and cells with double-sector centerpieces. Protein samples were studied at a concentration of 13 μM in 10 mM HEPES (pH 7.4) (at 25°C), 120 mM NaCl, 0.25% glycerol at 4°C, employing a rotor speed of 40,000 rpm. Radial absorbance scans were collected at a wavelength of 280 nm in 1 min intervals. Data were analyzed with SEDFIT (
Phosphorylation motifs for ASK1 kinases were determined by using a positional scanning peptide library approach essentially as described before (
The protein was denatured by boiling, cysteine residues were reductively alkylated, and then a tryptic digest was performed overnight (100:1 protein/enzyme ratio). The peptides were separated on a Dionex 3000 nano-LC system with a C18 Pepmap column by using a water/acetonitrile gradient with 0.1% formic acid and analyzed with a Bruker HCT Ultra ion trap in MS/MS mode. Alternating fragmentation cycles were performed in data-dependent MS/MS by using collision-induced dissociation (CID) and electron transfer dissociation (ETD), the data were submitted to Mascot searches (
ASK1-WT and ASK1-T838 (human; T845 for murine) were described previously (
Cell lysates were subjected to SDS-PAGE followed by immunoblot (IB) with a specific antibody (e.g., anti-HA) followed by HRP-conjugated anti-mouse secondary antibody. Protein was detected by chemiluminescence with an ECL kit according to the instructions of the manufacturer (Amersham Life Science).
Initial screens were set up with ASK1 kinase domain and several high-affinity small-molecular inhibitors. Crystals appeared in several conditions when 1 mM staurosporine was added to the protein. Screen conditions that yielded crystals all contained 20%–25% PEG 4000 or PEG 6000, 0.2 M salt, and had a pH around 6.0 (buffered or unbuffered). After optimisation, diffraction quality needle-like crystals were obtained from 25% PEG3350, 0.17 M (NH4)2SO4, and 15% glycerol with average dimensions 0.2 × 0.05 × 0.05 mm3 and were mounted with a loop and flash frozen by plunging into liquid nitrogen. Datasets were collected at the PXII beamline at the Swiss Light Source with a MAR225 detector at 0.972 Å.
Selenomethionine-labeled protein did not yield crystals using the same crystallization condition, and initial screening was repeated. Eventually, needle-like crystals were obtained from 18% PEG6000 and 0.1 M H3Cit/Na3Cit (pH 4.9). A SAD dataset was collected at the PXII beamline at the SLS by using the selenium peak wavelength (0.9789 Å, determined from a fluoresence scan). Diffraction images were processed with XDS (
Although molecular replacement solutions could be obtained by employing either an ensemble of most similar structures (29%–31% sequence identity, including only the C-terminal domain) or a homology model as search model, refinement was unstable and diverged. Unfortunately, the anomalous signal in the selenomethione-labeled protein was too weak to result in structure solution on its own. Although selenium positions could be located from the anomalous data with SHELXD (
Initially, the homology model that was used in molecular replacement of the unlabeled protein was used in Phaser (
The crystal structure reported in this paper has been deposited in the Protein Data Bank,
The Structural Genomics Consortium is a registered charity (number 1097737) that receives funds from the Canadian Institutes for Health Research, the Canadian Foundation for Innovation, Genome Canada through the Ontario Genomics Institute, GlaxoSmithKline, Karolinska Institutet, the Knut and Alice Wallenberg Foundation, the Ontario Innovation Trust, the Ontario Ministry for Research and Innovation, Merck & Co., Inc., the Novartis Research Foundation, the Swedish Agency for Innovation Systems, the Swedish Foundation for Strategic Research, and the Wellcome Trust. H.Z. and W.M. acknowledges support by grants from National Institutes of Health grants R01 HL-65978-5 and P01HL070295-6 to W.M. W.M. is an Established Investigator of the American Heart Association (0440172N). B.E.T. acknowledges support from NIH grant R01GM079498.
Supplemental Data include the melting profiles of the identified inhibitors (Figure S1) as well as the chemical structures (Table S1), characterization of the autophosphorylation sites by mass spectroscopy (Figure S2), quantified peptide array data (Table S2), and detailed description of interaction in the dimer interface (Table S3) and are available at
Overall Structures of ASK1 and Sequence Comparison to PAK1
(A) Domain architecture of ASK1. Coiled-coil domains are shown in blue, the kinase domain in red, and the 14-3-3 binding site in green. Predicted domain boundaries (residues) are given in the numbers above the sketch.
(B) Ribbon diagram showing a structural overview. Secondary structure elements were determined with the program ICM Pro 3.4-8 (Molsoft, LLC) and have been labeled according to the nomenclature established for PKA (
(C) Superimposition of ASK1 (red) with its closes structural neighbor PAK1 (yellow).
(D) Structure-based sequence alignment of ASK1 with PAK1. Secondary structure elements of ASK1 are also shown and labeled. Autophosphorylation sites identified by mass spectrometry are indicated by “P.” Residues not included in the model due to disorder are indicated by lower case letters.
Binding of Stauroporine
Main interacting active site residues with the ATP competitive inhibitor staurosporine are shown in ball-and-stick representation. Hydrogen bonds formed between the ligand and the protein are shown as dotted lines.
Activation Segment of ASK1
(A) Interaction between the helix αC and the DFG motif. Hydrogen bonds are shown as dotted lines.
(B) Hydrogen bond network stabilizing N- and C-terminal portion of the activation segment and link the ASK1 activation segment to the catalytic loop residue Arg802.
(C) Interaction stabilizing the activation segment in the active and phosphorylated kinase PAK4 (
Dimerization of ASK1 Kinase Domain
(A) Sedimentation velocity and equilibrium results of ASK1. Sedimentation velocity plot of the differential sedimentation coefficient distribution, c(s), versus the apparent sedimentation coefficient corrected to water at 20°C,
(B) Sedimentation equilibrium experiment employing a rotor speed of 10,000 rpm. The solid line denotes a fitted curve resulting from global nonlinear regression analysis with a self-association model. The residuals for the fit are shown in the upper panel of the graph. The determined dissociation constant for the dimer was (KD) of 0.22 ± 0.2 μM.
(C) Dimer interface spanning almost the entire side of ASK1 kinase domain. Both molecules interact in a head-to-tail orientation.
(D) Details of interactions located in the dimer interface.
Substrate Specificity of ASK1 and Identification of Autophosphorylation Sites
(A) Phosphorylation motifs for ASK1. Biotinylated peptides bearing the indicated residue at the indicated position relative to a central Ser/Thr phosphoacceptor site were subjected to phosphorylation by ASK1 with radiolabeled ATP. Aliquots of each reaction were subsequently spotted onto a streptavidin membrane, which was washed, dried, and exposed to a phosphor screen. Shown is a representative array from three separate experiments. Quantified spot intensities representing the average of the three runs are provided in
(B) Consensus sequence determined from the peptide array data. The consensus sequence is shown in bold and alternative residues are indicated at each position by smaller italic letters. The site of phosphorylation is indicated in red and by a star (∗). The three autophosphorylation sites are also shown, and residues matching the consensus sequence are highlighted with yellow boxes.
(C) Activation segments of the known ASK1 substrates of the MKK family of kinases. Residues phosphorylated by activation are highlighted in red.
(D) Location of the three autophosphorylation sites in ASK1. Phosphorylated residues are labeled in red and are shown as spheres, whereas neighboring residues are labeled in blue and are indicated in ball-and-stick representation. The interacting ASK1 dimer is shown in green.
Effects of Mutation at T813A, T838A, and T842A on ASK1 Activity
(A) 293T cells were transfected with various ASK1 mutants in the presence of an ASK1-JNK-dependent reporter gene. A renilla construct was cotransfected as an internal control. HIPK1-WT and T838A were used as controls. Both luciferase and renilla units were measured. Relative luciferase activities are presented from mean of duplicate samples by taking vector control as 1. Similar results were obtained from two additional experiments. Data are presented as mean of duplicates from two independent experiments. ASK1 protein expression was determined by Western blot (lower panel) with anti-HA-POD (anti-HA-conjugated peroxidase; Roche).
(B) The ASK signaling pathway was reconstituted in vitro with recombinant ASK1 and its phosphorylation site mutants, MKK6 as well as p38. p38 phosphorylation was detected with an antibody specific phosphorylated p38. Corresponding Coomassie gels as well as a his-tag-specific antibody has been used to demonstrate identical loading concentrations of the samples.
Data Collection and Refinement Statistics
| Native | Selenomethionine | |
|---|---|---|
| Space group | P6522 | P41212 |
| Cell (Å) | a = b = 78.16; c = 423.28 | a = b = 92.58; c = 85.19 |
| Number of reflections | 536667 | 116678 |
| Number of unique data | 35817 | 8659 |
| Resolution (Å) |
47.0–2.30 (2.4–2.3) | 46.3–2.90 (3.0–2.9) |
| Completeness |
99.3% (93.9%) | 99.6% (96.7%) |
| I/σ(I) |
17.7 (1.9) | 19.5 (2.8) |
| Rint |
0.0991 (0.5924) | 0.1047 (0.6648) |
| Rwork/Rfree | 0.204/0.257 | - |
| Rmsd bond length (Å) | 0.014 | - |
| Rmsd bond angle | 1.52° | - |
| B-factors (overall) (mainchain, sidechain, solvent) | 38.5 (38.4, 39.8, 33.6) | - |
| Ramachandran | Most favored: 91.6%; additionally allowed: 8.2%; generously allowed: 0.2%; disallowed: 0% |
Values in brackets indicate values in the highest resolution shell.